Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Clinuvel Pharmaceuticals (CUV) vs. Competitors

118 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
AU:CUVClinuvel Pharmaceuticals AUD 7.29AUD 372.59M10.60-32.81%Moderate BuyUnlock the AU:CUV analyst price target with TipRanks PremiumAU:CUVUnlock the AU:CUV top-analyst price target with TipRanks Premium
AU:ACRAcrux AUD 0.01AUD 6.12M-7.14-37.50%―Unlock the AU:ACR analyst price target with TipRanks PremiumAU:CUV vs AU:ACRUnlock the AU:ACR top-analyst price target with TipRanks Premium
AU:SPLStarpharma Holdings LimitedAUD 0.43AUD 205.24M-24.273.91%―Unlock the AU:SPL analyst price target with TipRanks PremiumAU:CUV vs AU:SPLUnlock the AU:SPL top-analyst price target with TipRanks Premium
AU:PYCPYC Therapeutics LimitedAUD 1.74AUD 1.71B-28.0041.06%Strong BuyUnlock the AU:PYC analyst price target with TipRanks PremiumAU:CUV vs AU:PYCUnlock the AU:PYC top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 27.63M-0.28-92.00%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumAU:CUV vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:BIOBiome Australia LtdAUD 0.35AUD 83.31M21.74-18.60%Moderate BuyUnlock the AU:BIO analyst price target with TipRanks PremiumAU:CUV vs AU:BIOUnlock the AU:BIO top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
AU:CUVClinuvel Pharmaceuticals 7.29-3.59-33.00%
AU:ACRAcrux 0.01-0.00-33.33%
AU:SPLStarpharma Holdings Limited0.420.037.87%
AU:PYCPYC Therapeutics Limited1.740.4030.16%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.67%
AU:BIOBiome Australia Ltd0.35-0.09-19.54%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts